We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Potential Maternal Blood Test May Predict Fetal Complications

By LabMedica International staff writers
Posted on 03 Nov 2016
Researchers have found that the protein DLK1 in blood of pregnant women is required for maternal metabolic adaptations to pregnancy and is associated with fetal growth restriction, and suggested that DLK1 could be used as a prenatal diagnostic marker in a relatively non-invasive test to help determine health of newborns and aid decisions on early elective deliveries.

In an initial study, led by researchers at Queen Mary University of London (QMUL; London, UK), tests in pregnant mice and a small sample of women showed that an abnormally low level of DLK1 in maternal blood was a good predictor of poor fetal growth and complications of pregnancy, and could be used as a non-invasive prenatal diagnostic.

“At the moment, there are very few ways of predicting which pregnancies will go wrong, and which small babies are small because they are not getting enough nutrition while in the womb, and which are small simply because of their genes,” said lead researcher Dr Marika Charalambous from QMUL, “It’s incredibly important to start developing tests that can give an obstetrician much more information on the pregnancy before delivery, so that they can intervene before complications come to crisis point. More...
Measuring DLK1 levels in the mother’s blood could be a reliable and non-invasive way of predicting whether there are likely to be complications; especially those that cause reduced nutrient supply to the baby. In those instances, you really need to get the baby out quickly, so women could opt to have an early elective delivery.”

DLK1 is present at high levels in maternal blood during pregnancy, in humans and rodents. But little has been known about its source, functional role, and whether it can indicate anything about fetus health. To determine the source of DLK1 in the blood of pregnant mothers, the researchers initially used mice experiments that involved DLK1 gene knockout in either the fetus or mother, and measuring DLK1 in maternal blood. They found that the protein originates from the embryo, suggesting that maternal blood DLK1 levels could provide a direct readout about the embryo’s biological state.

The team then looked at how DLK1 affects pregnant mouse metabolism. When fasting for 24 hours, mice and humans begin undergoing ketosis (burning fat stores as an alternative energy source). When DLK1 was inactivated in pregnant mice, their fasting response was impaired by being unable to begin ketosis. This indicated the importance of DLK1 in providing energy for the fetus and its growth, and maternal blood DLK1 levels were found to be a good predictor of offspring mass.

Finally, with help from the POPs study at University of Cambridge, the researchers studied 129 first-time mothers, measuring blood DLK1 levels and recording pregnancy outcomes. They found that low DLK1 levels were associated with reduced growth of the fetus resulting from pregnancy complications, including poor blood flow through the umbilical cord.

The researchers warn that further clinical studies in humans will be required to determine DLK1’s potential as a prenatal diagnostic.

The study, by Cleaton MAM et al, was published online October 24, 2016, in the journal Nature Genetics.

Related Links:
Queen Mary University of London



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Pathology

view channel
Image: Schematic diagram of multimodal single-cell MSI using tapping-mode scanning probe electrospray ionization (Photo courtesy of Yoichi Otsuka)

New Technology Improves Understanding of Complex Biological Samples

Tissues are composed of a complex mixture of various cell types, which complicates our understanding of their biological roles and the study of diseases. Now, a multi-institutional team of researchers... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.